Hoth Therapeutics (HOTH)
(Delayed Data from NSDQ)
$1.16 USD
-0.01 (-0.85%)
Updated Apr 26, 2024 03:58 PM ET
After-Market: $1.18 +0.02 (1.72%) 7:58 PM ET
2-Buy of 5 2
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HOTH 1.16 -0.01(-0.85%)
Will HOTH be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for HOTH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HOTH
Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data
HOTH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for HOTH
Hoth Therapeutics files to sell 5.03M shares of common stock for holders
Hoth Therapeutics files to sell 5.03M shares of common stock for holders
Promising Preclinical Alzheimer’s Candidate and Diverse Pipeline Bolster Hoth Therapeutics’ Buy Rating
Hoth Therapeutics price target raised by 50c at EF Hutton, here's why
Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds